Teva Pharmaceutical Industries ROE 2006-2018 | TEVA

Current and historical return on equity (ROE) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Teva Pharmaceutical Industries ROE for the three months ending September 30, 2018 was 21.83%.
Teva Pharmaceutical Industries ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-11.06B $19.13B -57.19%
2018-06-30 $-10.26B $19.37B -46.35%
2018-03-31 $-16.05B $20.10B -65.01%
2017-12-31 $-16.53B $18.75B -57.78%
2017-09-30 $-5.96B $30.30B -18.26%
2017-06-30 $-6.15B $29.61B -17.89%
2017-03-31 $0.08B $35.75B 0.22%
2016-12-31 $0.07B $34.99B 0.20%
2016-09-30 $1.59B $37.03B 4.91%
2016-06-30 $1.35B $32.02B 4.66%
2016-03-31 $1.70B $30.59B 6.37%
2015-12-31 $1.57B $29.93B 6.38%
2015-09-30 $1.78B $22.90B 7.72%
2015-06-30 $2.55B $23.09B 10.98%
2015-03-31 $2.76B $22.68B 11.82%
2014-12-31 $3.06B $23.36B 13.05%
2014-09-30 $2.75B $23.67B 11.83%
2014-06-30 $2.58B $23.59B 11.27%
2014-03-31 $1.38B $23.03B 6.17%
2013-12-31 $1.27B $22.64B 5.67%
2013-09-30 $1.21B $22.39B 5.39%
2013-06-30 $0.42B $21.61B 1.85%
2013-03-31 $1.73B $22.81B 7.57%
2012-12-31 $1.96B $22.87B 8.53%
2012-09-30 $2.15B $23.07B 9.39%
2012-06-30 $3.14B $22.89B 13.76%
2012-03-31 $2.86B $23.20B 12.39%
2011-12-31 $2.76B $22.34B 11.97%
2011-09-30 $3.02B $22.94B 13.17%
2011-06-30 $3.16B $23.75B 13.94%
2011-03-31 $3.38B $23.13B 15.68%
2010-12-31 $3.33B $22.00B 16.10%
2010-09-30 $2.94B $21.71B 14.69%
2010-06-30 $2.54B $19.36B 13.08%
2010-03-31 $2.26B $19.68B 11.89%
2009-12-31 $2.00B $19.26B 11.03%
2009-09-30 $0.93B $19.30B 5.36%
2009-06-30 $0.92B $17.85B 5.66%
2009-03-31 $0.94B $16.14B 6.02%
2008-12-31 $0.64B $16.30B 4.19%
2008-09-30 $1.89B $14.84B 13.05%
2008-06-30 $1.78B $15.08B 12.70%
2008-03-31 $1.76B $14.40B 13.24%
2007-12-31 $1.95B $13.72B 15.59%
2007-09-30 $1.84B $12.92B 15.51%
2007-06-30 $1.92B $12.06B 17.03%
2007-03-31 $1.90B $11.39B 17.63%
2006-12-31 $0.55B $11.14B 5.34%
2006-09-30 $0.39B $10.58B 4.36%
2006-06-30 $0.05B $9.90B 0.66%
2006-03-31 $-0.20B $9.22B -3.00%
2005-12-31 $1.07B $6.04B 19.30%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $23.927B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.860B 9.42
Mylan (MYL) United Kingdom $18.439B 7.59
Bausch Health Cos (BHC) Canada $9.314B 6.74
Dr Reddy's Laboratories (RDY) India $5.645B 22.54
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.589B 4.32
Supernus Pharmaceuticals (SUPN) United States $2.357B 22.33
Amphastar Pharmaceuticals (AMPH) United States $0.978B 106.05
Akorn (AKRX) United States $0.853B 0.00
Homology Medicines (FIXX) United States $0.748B 0.00
Assembly Biosciences (ASMB) United States $0.570B 0.00
CymaBay Therapeutics (CBAY) United States $0.536B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.451B 0.00
Voyager Therapeutics (VYGR) United States $0.384B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.315B 0.00
Teligent (TLGT) United States $0.170B 0.00
Sol-Gel Technologies (SLGL) Israel $0.135B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.095B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.032B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00